Human papillomavirus: screening and vaccination

Elena Evgen’yevna Roik; Aleksey Nikolaevich Baranov; Maksim Vadimovich Usynin

doi:10.17816/JOWD63638-43

Journal of obstetrics and women's diseases ›› 2014, Vol. 63 ›› Issue (6) : 38 -43. DOI: 10.17816/JOWD63638-43

Articles

research-article

Human papillomavirus: screening and vaccination

Author information +

History +

PDF

Abstract

Every year, 500 000 women worldwide are diagnosed with cervical cancer. Currently, there is no doubt that certain types of human papillomavirus (HPV) do act as causative agents of cervical cancer. Nowadays there are more than 150 different types of HPV are known. Certain types of viruses by affecting the epithelium of humans and animals lead to appearance of warts or papillomas, others lead to malignancy of squamous epithelium. The most common HPV types are 16 and 18, cause cervical cancer. Vaccination and screening are the most effective tools for preventing cervical cancer. Preventive vaccines are currently registered and actively used in many countries around the world.

Keywords

cervical cancer / human papillomavirus (HPV) / vaccination / vaccine

Cite this article

Download citation ▾

Elena Evgen’yevna Roik, Aleksey Nikolaevich Baranov, Maksim Vadimovich Usynin. Human papillomavirus: screening and vaccination. Journal of obstetrics and women's diseases, 2014, 63(6): 38-43 DOI:10.17816/JOWD63638-43

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Роговская С. И., Михеева И. В., Шипулина О. Ю., Минкина Г. Н., Минкина Г. Н., Подзолкова Н. М., Радзинский В. Е., Шипулин Г. А. Распространенность папилломавирусной инфекции в России. Эпидемиология и вакцинопрофилактика. 2012; 1: 25-33.

[2]	Cutts F. T., Franceschi S., Goldie S., Castellsague X., de Sanjose S., Garnett G., Edmunds W. J., Claeys P., Goldenthal K. L., Harper D. M., Markowitz L. Human papillomavirus and HPV vaccines: a review. Bull World Health Org. 2007; 85: 719-26.

[3]	De Villiers E. M., Fauquet C., Broker T. R., Bernard H. U., zur Hausen H. Classification of papillomaviruses. Virology. 2004; 324: 17-27.

[4]	Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond). 2006; 110 (5): 525-41.

[5]	Dunne E. F., Unger E. R., Sternberg M., McQuillan G., Swan D. C., Patel S. S., Markwitz L. E. Prevalence of HPV infection among females in the United States. JAMA. 2007; 297: 813-9.

[6]	Ferlay J., Shin H. R., Bray F., Forman D., Mathers C., Parkin D. M. Globocan 2008 v 1.2, Cancer Incidence and Mortality Worldwide: IARK CancerBase No 10 [Internet]. Lyon, France: International Agency of Research on Cancer; 2010. [Available at: http://globocan.iarc.fr].

[7]	Grabowska A. K., Riemer A. B. The Invisible Enemy-how human papillomaviruses avoid recognition and clearance by the host immune system. Open Virol J. 2012; 6: 249-56.

[8]	Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002; 2 (5): 342-50.

[9]	Hausen H. Papillomaviruses in human cancer. Appl Pathol. 1987; 5 (1): 19-24.

[10]	Hausen H. Papillomaviruses in the causation of human cancers - a brief historical account. Virology. 2009; 384: 260-265.

[11]	National Cancer Registry Project (NCRP) Biennial Report. 2007. New Delhi: Indian Council of Medical Research.

[12]

Paavonen J., Jenkins D., Bosch F. X., Naud P., Salmeron J., Wheeler C. M., Chow S. N., Apter D. L., Kitchener H. C., Castellsague X., de Carvalho N. S., Skinner S. R., Harper D. M., Hedrick J. A., Jaisamrarn U., Limson G. A., Dionne M., Quint W., Spiessens B., Peeters P., Struyf F., Wieting S. L., Lehtinen M. O., Dubin G. HPV PATRICIA study group. 2007. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007; 369 (9580): 2160-2170 Erratum in: Lancet. 2007; 370 (9596): 1414.

[13]	Parkin D. M., Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine. 2006; 24 (Suppl 3): S11-25.

[14]	Bray F., Lortet-Tieulent J., Znaor A., Brotons M., Poljak M., Arbyn M. Patterns and trends in human papillomavirus-related diseases in Central and Eastern Europe and Central Asia. Vaccine. 2013 Dec 31;31 Suppl 7: H32-45. doi: 10.1016/j.vaccine.2013.02.071.

[15]

Rogovskaya S.I, Shabalova I.P, Mikheeva I.V, Minkina G.N, Podzolkova N.M, Shipulina O.Y, Sultanov S.N, Kosenko I.A, Brotons M., Buttmann N., Dartell M., Arbyn M., Syrjanen S., Poljak M. Human Papillomavirus Prevalence and Type-Distribution, Cervical Cancer Screening Practices and Current Status of Vaccination Implementation in Russia, the Western Countries of the former Soviet Union, Caucasus Region and Central Asia. Vaccine. 2012.

[16]	Fahey M. T., Irwig L., Macaskill P. Meta-analysis of Pap-test accuracy. Am J Epidemiol 1995; 141: 680-9.

[17]	Wang K. L. Human papillomavirus and vaccination in cervical cancer. Taiwan J Obstet Gynecol. 2007; 46: 352-62.

[18]	Ronco G., Anttila A. Cervical cancer screening in Europe - changes over the last 9 years. Eur J Cancer. 2009 Oct; 45 (15): 2629-31. doi: 10.1016/j.ejca.2009.07.021. Epub 2009 Aug 18.

[19]

Anttila A., Ronco G. Working Group on the Registration and Monitoring of Cervical Cancer Screening Programmes in the European Union; within the European Network for Information on Cancer (EUNICE). Description of the national situation of cervical cancer screening in the member states of the European Union. Eur J Cancer. 2009 Oct; 45 (15): 2685-708. doi: 10.1016/j.ejca.2009.07.017. Epub 2009 Sep 8.

[20]	Anttila A., Nieminen P. Cervical cancer screening programme in Finland. Eur J Cancer. 2000 Nov; 36 (17): 2209-14.

[21]	Korfage I. J., Essink-Bot M. L., Daamen R., Mols F., van Ballegooijen M. Women show mixed intentions regarding the uptake of HPV vaccinations in pre-adolescents: a questionnaire study. Eur J Cancer. 2008 Jun; 44 (9): 1186-92. doi: 10.1016/j.ejca. 2008.03.018.

[22]	Bosch F. X., Broker T. R., Moscicki A. B., Gillison M. L., Doorbar J., Stern P. L., Stanley M., Arbyn M., Poljak M., Brotons M., Alemany L., Albero G., Diaz M. Comprehensive control of human papillomavirus infections and related diseases. Vaccine. 2013 Dec 31;31 Suppl 7: H1-31.

[23]	Sanner K., Wikström I., Strand A., Lindell M., Wilander E. Self-sampling of the vaginal fluid at home combined with high-risk HPV testing. Br J Cancer. 2009 Sep 1; 101 (5): 871-4.

[24]	ACOG Practice Bulletin Number 131: Screening for cervical cancer. Obstet Gynecol. 2012 Nov; 120 (5): 1222-38.

[25]	Hansena B., Susanne K., Lisen A., Kirsten E. Jensen B., Nygårda M. Human papillomavirus (HPV) vaccination and subsequent sexual behaviour: Evidence from a large survey of Nordic/Vaccine, 2014 3 September; 32 (39): 4945-53.

[26]	В. И. Чиссова, В. В. Старинского, Г. В. Петровой. Состояние онкологической помощи населению россии в 2010 году / под. ред. М.: ФГУ «МНИОИ им. П. А. Герцена» Минздравсоцразвития России, 2011; 188.

[27]	Махсон А. Н., Сдвижков А. М., Евтягин В. В. и др. Скрининг для выявления рака шейки матки в Москве // Протокол заседания московского общества онкологов (29 марта 2012 г.). http://www.oncology.ru.